KRAS and cancer: To clarify the specific signaling pathways regulated by CD44, we performed GSEA and confirmed that CD44 mainly participated in inflammatory responses, interferon, interleukin, EMT, and KRAS signaling pathways in pan-cancer (Figure 4C).